(Q37832729)

24 August 2017

1 reference

title

Cost effectiveness of treatments for inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

24 August 2017

main subject

0 references

inflammation

0 references

cost-effectiveness analysis

1 reference

Keith Bodger

1

1 reference

24 August 2017

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

29

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

387-401

1 reference

Cost of illness of Crohn's disease

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Economic burden of inflammatory bowel disease: a UK perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

The costs of Crohn's disease in the United States and other Western countries: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

The direct and indirect cost burden of Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Costs of inflammatory bowel disease in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Open access follow up for inflammatory bowel disease: pragmatic randomised trial and cost effectiveness study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Surveillance issues in inflammatory bowel disease: ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Usefulness of an elemental diet in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Infliximab use in Crohn's disease: impact on health care resources in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Infliximab decreases resource use among patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Cost-utility of initial medical management for Crohn's disease perianal fistulae.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Management for severe Crohn's disease: a lifetime cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Economics of biological therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Crohn's disease: step up or top down therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584820-000000000-00000

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease

21 January 2018

1 reference

12 December 2020

Medical therapy for Crohn's disease: top-down or step-up?

1 reference

12 December 2020

Inflammatory bowel disease: medical cost algorithms

1 reference

12 December 2020

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

12 December 2020

Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis

1 reference

12 December 2020

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

12 December 2020

Maintenance therapy versus episodic therapy with infliximab for Crohn's disease

1 reference

12 December 2020

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

1 reference

12 December 2020

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults

1 reference

12 December 2020

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

1 reference

12 December 2020

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

1 reference

12 December 2020

Inflammatory bowel disease: costs-of-illness

1 reference

12 December 2020

The cost of hospitalization in Crohn's disease

1 reference

12 December 2020

Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease

1 reference

12 December 2020

The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States

1 reference

12 December 2020

Inflammatory bowel diseases: health care and costs in Sweden in 1994

1 reference

12 December 2020

Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial

1 reference

12 December 2020

A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis

1 reference

12 December 2020

The economic cost of ulcerative colitis: a national estimate for 1968.

1 reference

12 December 2020

Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis.

1 reference

12 December 2020

Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis

1 reference

12 December 2020

Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients

1 reference

12 December 2020

A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis

1 reference

12 December 2020

Cost-Effectiveness of Budesonide Controlled Ileal Release (CIR) Capsules as Maintenance Therapy versus No Maintenance Therapy for Ileocaecal Crohn's Disease in Sweden

1 reference

12 December 2020

10.2165/11584820-000000000-00000

Identifiers

DOI

1 reference

24 August 2017

1 reference